Come closer: a neurobiological analysis of the prosocial effects of MDMA
Double-blind, placebo-controlled crossover study (n=24) testing single-dose MDMA (75 mg), intranasal oxytocin (48 IU), MDMA+5-HT1A blocker (pindolol 20 mg), and placebo in healthy MDMA-experienced volunteers to investigate prosocial effects and mechanisms.
Details
Randomized, double-blind, placebo-controlled within-subject crossover (Latin square) with four test days separated by a minimum 7-day washout; treatments: MDMA 75 mg oral capsule, MDMA+5-HT1A blocker (pindolol 20 mg), intranasal oxytocin (48 IU total), and placebo.
Outcomes include objective computer tasks of empathy and social interaction, control word-learning task, and blood measurements of MDMA, oxytocin and other treatment concentrations; also assessment of the moderating effect of serotonin transporter genotype.